Table 1.

Characterization of sOva encoding AAV preparations

Name	Capsid	Vector genome	Vector genomes/μL	Capsids/μL	Cap/vg
AAV2::sOva	unmodified	sOva, ss	6.15 ×108	6.60 × 108	1.1
AAV-Vac_Ova8587a	Ova CD8 epitope, position I-587	sOva, ss	4.68 × 108	8.60 × 108	1.8
AAV-Vac_Ova4587a	Ova CD4 epitope, position I-587	sOva, ss	6.34 × 108	1.17 × 109	1.8
AAV-Vac_Ova4+8VP2	Ova CD4 + CD8 epitope, VP2 fusion	sOva, ss	1.58 × 108	4.49 × 107	0.3
AAV-Vac_cOvaVP2	full-length cOva, VP2 fusion	sOva, ss	2.02 × 108	3.16 × 108	1.6

sOva, secreted full-length ovalbumin; cOva, cytoplasmic ovalbumin; ss, single-stranded vector-genome conformation; a, produced as hybrids with a mixture of modified and wild-type AAV2 capsid proteins.

Following iodixanol density gradient ultracentrifugation and AVB-column chromatography purification, including a dialysis step, the genomic and capsid titers of the indicated sOva-encoding AAV preparations were determined by qPCR and ELISA, respectively. Based on these values, the packaging efficiency as capsids (Cap)/vector genome (vg) was calculated.